Mandy H. Lawson

Oncology R&D
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors.

Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors.

Journal: Molecular cancer therapeutics

Published: July 30, 2025

Real-time cell viability monitoring for high-throughput drug screening using tumor xenograft-derived cells.

Real-time cell viability monitoring for high-throughput drug screening using tumor xenograft-derived cells.

Journal: Cell reports methods

Published: June 04, 2025

The EstroGene2.0 database for endocrine therapy response and resistance in breast cancer.

The EstroGene2.0 database for endocrine therapy response and resistance in breast cancer.

Journal: NPJ breast cancer

Published: August 22, 2024

EstroGene2.0: A multi-omic database of response to estrogens, ER-modulators, and resistance to endocrine therapies in breast cancer.

EstroGene2.0: A multi-omic database of response to estrogens, ER-modulators, and resistance to endocrine therapies in breast cancer.

Journal: bioRxiv : the preprint server for biology

Published: July 15, 2024

Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC.

Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC.

Journal: Communications biology

Published: January 17, 2024

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.

Journal: Cancer research

Published: March 03, 2023

Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists.

Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists.

Journal: Journal of medicinal chemistry

Published: February 02, 2023

Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer.

Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer.

Journal: Oncogene

Published: July 02, 2022

Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist.

Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist.

Journal: Journal of medicinal chemistry

Published: September 10, 2020

Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists.

Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists.

Journal: Journal of medicinal chemistry

Published: January 15, 2019

Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer.

Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer.

Journal: Molecular cancer therapeutics

Published: June 11, 2017

Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.

Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.

Journal: Cancer discovery

Published: December 23, 2015

Showing 1-12 of 15

Last Updated: 09/26/2026